RET mutations and medullary thyroid cancer

Journal of the Formosan Medical Association

Volumn 110, Issue 11, 2011, Pages 731-

  Lin, Chia Chi ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET;

CODON; FAMILY HISTORY; GENE MUTATION; GENOTYPE; GERM LINE; HUMAN; LETTER; MULTIPLE ENDOCRINE NEOPLASIA; PHENOTYPE; THYROID CANCER;

CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 82255192442     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2011.09.017     Document Type: Letter

References (3)

1. Chang C.F., Yang W.S., Su Y.N., Wu I.L., Chang T.C. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in Taiwan. J Formos Med Assoc 2009, 108:402-408.
2. Phay J.E., Shah M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010, 16:5936-5941.
3. Kurzrock R., Sherman S.I., Ball D.W., Forestiere A.A., Cohen R.B., Mehra R., et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011, 29:2660-2666.